The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer

被引:0
|
作者
C Sawka
I Olivotto
A Coldman
V Goel
E Holowaty
TG Hislop
机构
[1] University of Toronto,Department of Medicine
来源
British Journal of Cancer | 1997年 / 75卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
This study evaluated the impact of province-wide treatment guidelines on consistency of adjuvant therapy for node-negative breast cancer. A retrospective population-based cohort study was conducted in the Canadian provinces of British Columbia, which has province-wide guidelines, and Ontario, which does not. All eligible 1991 incident cases of node-negative breast cancer in British Columbia (n = 942) and a similar number of randomly selected 1991 incident cases in Ontario (n = 938) were reviewed. Consistency of adjuvant therapy received was evaluated by stratifying cases into discrete diagnostic groups using several grouping systems, and by then comparing the distribution of treatments received within each diagnostic group in the two provinces. Recursive partitioning was also performed. We observed that patterns of pathology reporting were consistent with awareness of the factors used in the British Columbia guidelines to define indications for adjuvant therapy. Consistency of care was greater in British Columbia than in Ontario by all diagnostic grouping systems and by recursive partitioning (P < 0.001), and the observed patterns in British Columbia corresponded to the British Columbia guidelines. We conclude that population-based treatment guidelines can play a role in promoting consistent patterns of adjuvant therapy for women with node-negative breast cancer.
引用
收藏
页码:1534 / 1542
页数:8
相关论文
共 50 条
  • [41] Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC).
    Steenbruggen, Tessa Gerjanne
    Van Ramshorst, Mette S.
    van Werkhoven, Erik
    Dezentje, Vincent O.
    Siesling, Sabine
    Linn, Sabine C.
    Sonke, Gabe S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] NODE-NEGATIVE BREAST-CARCINOMA TREATED WITHOUT ADJUVANT SYSTEMIC THERAPY
    SPAULDING, CA
    GOLDSTEIN, G
    MORRISON, G
    HOLTHAUS, W
    GARBER, B
    SOUTHERN MEDICAL JOURNAL, 1992, 85 (04) : 355 - 364
  • [43] Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer
    Oladeru, Oluwadamilola T.
    Singh, Anurag K.
    Ma, Sung Jun
    JAMA NETWORK OPEN, 2020, 3 (09)
  • [44] ADJUVANT CHEMOTHERAPY AND ENDOCRINE THERAPY FOR NODE-POSITIVE AND NODE-NEGATIVE BREAST-CARCINOMA
    ALBAIN, KS
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1989, 32 (04): : 835 - 857
  • [45] APPROPRIATENESS OF ADJUVANT SYSTEMIC THERAPY FOR AXILLARY NODE-NEGATIVE BREAST-CANCER - A PHYSICIAN OPINION SURVEY
    SAWKA, CA
    OCONNOR, AM
    LLEWELLYNTHOMAS, HA
    TO, T
    PINFOLD, SP
    HARRISONWOERMKE, D
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) : 1459 - 1469
  • [46] NODE-NEGATIVE MINIMAL INVASIVE BREAST-CANCER PATIENTS ARE NOT CANDIDATES FOR ROUTINE SYSTEMIC ADJUVANT THERAPY
    ROSNER, D
    LANE, WW
    CANCER, 1990, 66 (02) : 199 - 205
  • [47] Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cm
    Christy A. Russell
    Current Oncology Reports, 2003, 5 (1) : 72 - 77
  • [48] Reply to improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer - A United States population-based assessment
    Artinyan, Avo
    Kim, Joseph
    CANCER, 2008, 113 (05) : 1111 - 1112
  • [49] NODE-NEGATIVE BREAST-CANCER
    COOMBES, RC
    PATHOLOGIE BIOLOGIE, 1994, 42 (10): : 958 - 958
  • [50] Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer:: A randomized trial
    Goldhirsch, A
    Coates, AS
    Collins, J
    Thürlimann, B
    Senn, HJ
    Holmberg, S
    Lindtner, J
    Veronesi, A
    Cortés-Funes, H
    Castiglione-Gertsch, M
    Nasi, ML
    Egli, G
    Rabaglio, M
    Maibach, R
    Gerber, MI
    Hiltbrunner, A
    Gelber, R
    Price, K
    Bonetti, M
    Peterson, H
    Zahrieh, D
    Zelen, M
    Gelber, S
    O'Neill, A
    Litman, H
    Hinkle, R
    Isley, M
    Blacher, L
    Lippert, S
    Celano, J
    Gusterson, B
    Bettelheim, R
    Reed, R
    Viale, G
    Mallon, E
    Bernhard, J
    Hürny, C
    Gusset, H
    Mathys, N
    Cliffe, B
    Crivellari, D
    Monfardini, S
    Galligioni, E
    Magri, MD
    Veronesi, A
    Buonadonna, A
    Massarut, S
    Rossi, C
    Candiani, E
    Carbone, A
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (14): : 1054 - 1065